is a Biopharmaceutical Company developing anti-cancer immunotherapies

Learn More

Executive Summary

NeoTX is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy. With a strong research and development team, our strategy is to build a patented, proprietary and unique product pipeline to capitalize on technologies that NeoTX is developing independently and through collaborative partnerships and license agreements.


Asher Nathan



Dr. Asher Nathan has extensive biotech operating experience, having started biotech companies, Intelligene and ...

Read more
Marcel Rozencweig M.D.



Dr. Rozencweig is a medical oncologist with more than 40 years of experience and accumulated expertise in clinical trials and...

Read more
Ramona Lloyd PhD



Dr. Lloyd is a leading regulatory expert with over 20 years of experience in global regulatory affairs and quality assurance. ...

Read more
Robert Harow



Prior to co-founding NeoTX, Mr. Harow co-founded Zoticon Bioventures, where ...

Read more
Roger Kornberg PhD



Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the process by which genetic information ...

Read more
Dr. Michal Shahar


VP of R&D

Dr. Shahar previously served as VP of Research and Development at Efranat Ltd., an immuno-oncology drug ...

Read more


NeoTX is building a pipeline of differentiated cancer immunotherapies


T Cells can kill tumors but are often repressed

Our immune system is designed to kill cancer. The T cell, is the immune system’s killing machine: T cells can hunt down unhealthy cells like cancer and destroy them.  Each T cell identifies a unique signature on a cell’s surface, so only the right T cell can interact with the tumor. Besides T cells specificity, the tumor can produce repressive signals, “checkpoints”, essentially inactivating the T cell.

Checkpoint inhibitors reactivate T cells

Checkpoint inhibitor therapy (“CPI”), which reactivates the T cells, enabling them to kill tumors, continues to dominate the oncology market with 2018 sales of $16BN.  Since many tumors have signatures that are difficult for the immune system to identify, even when the checkpoint inhibitors reactivate the T cells, if the T cells can not recognize the tumor, then the drug will have no effect.  Therefore only a relatively small fraction of patients respond to checkpoint inhibitor drugs as a monotherapy, and despite the impressive revenues, these drugs do not actually help most patients. 

T cell redirection technologies can unlock the potential of checkpoint inhibitors

T cell redirection technologies (such as CAR T and BiTE) increase tumor recognition, thereby redirecting the T cells to the tumor, after they can become activated by CPIs.  While CAR T and BiTE technologies have been approved in some blood-based tumors, they are only in early clinical stage development in solid tumors, as there are many hurdles that need to be overcome for them to be effective in solid tumors.  CAR T suffers from serious safety concerns, manufacturing complexity and difficulties in getting the T cells through a hostile environment that surrounds the tumor. BiTE likewise has safety concerns as it can stimulate all T cells causing the immune system to go into overdrive, a condition known as cytokine release syndrome (CRS). Nevertheless, T cell redirection technologies have had high valuations including Kite Therapeutics sale to Gilead Pharmaceuticals for $12BN and Juno Therapeutics sale to Celgene for $9BN while still in phase II.

NeoTX’s “STR” platform Overview

NeoTX’s “STR” platform represents a potential paradigm shift in T cell redirection.  NeoTX’s STR drug, ANYARA, is comparatively easy to manufacture.  There are early clinical observations that ANYARA can redirect the traffic of T cells into solid tumors and clinical safety has been established in 300 patients.  The drug has not triggered serious CRS syndrome in patients.  The drug coats the tumor with bacterial components that are easy for the T cells to identify and directs them to the tumor.  Because only T cells that have the bacterial recognition signature are selectively stimulated there is less of a concern for safety

Clinical Trials

The first STR drug will enter the clinic, in combination with CPIs, in the second half of 2019. The trial will begin with a dose escalation trial designed to test its safety in combination with a CPI and will be followed by a cohort expansion in hard-to-treat patient populations.


In addition to ANYARA, NeoTX has other programs in immuno-oncology that are in research and development that seek to fill unmet medical needs.

To achieve success, NeoTX’s strategy for growth is to:

  • Discover, acquire and develop technologies that modulate antigen presentation or exploit other mechanisms to enhance the immune system’s ability to attack tumors.
  • Develop business partnerships with ANYARA.
  • Commercialize proprietary products through corporate alliances.
View Press Release


Feb 11, 2019 - Rehovot, Israel
NeoTX Therapeutics Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate the safety and activity of the combination of NeoTX’s naptumomab and AstraZeneca’s durvalumab in selected solid tumors

NeoTX Therapeutics, Ltd announced today that it has entered into a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics research and development arm, MedImmune, to support Phase 1b/2 studies investigating NeoTX’s naptumomab estafenatox (“naptumomab”) in combination with IMFINZI® (durvalumab). These studies are expected to begin in 2019. Naptumomab is the lead drug in NeoTX’s novel Selective T cell Redirection (“STR”) platform.
Naptumomab’s dual mechanism of action coats the tumor with a target that can be easily identified by T cells and then primes and redirects specific activated T cells that can identify that target, to the tumor.
Durvalumab is a human monoclonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and allows activated T cells to attack tumor cells.
The Phase 1b/2 studies will determine the maximum tolerated dose (MTD) of naptumomab in combination with durvalumab, evaluate the clinical response, safety and tolerability of the combination, as well as test for multiple pharmacodynamic parameters.
Under terms of the agreement, NeoTX and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in solid tumors. NeoTX will sponsor the study, while AstraZeneca will supply durvalumab. Up to 195 patients are planned to be enrolled in this multicenter, open-label study.
“We are pleased to work with AstraZeneca addressing the high unmet medical need of patients with tumors for which checkpoint inhibitor therapy has had little success,” said Asher Nathan, NeoTX Therapeutics’ Chief Executive Officer. “The safety profile of naptumomab alone and in combination with interferon has been demonstrated in clinical studies in hundreds of patients with solid tumors. Naptumomab can enhance T cell activation and infiltration in tumors and can remodel the immunosuppressive tumor microenvironment. In preclinical models, naptumomab has a synergistic effect with checkpoint inhibitors which could translate into durable responses in patients.”

About NeoTX:
NeoTX Therapeutics Ltd. is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology (
For more information contact
609 718 2305
CEO Asher Nathan x215 ( or
CFO Robert Harow x204 (
About Naptumomab Estafenatox:
Naptumomab estafenatox is the lead compound in NeoTX’s STR platform. The STR platform offers unique advantages in the field of T cell redirection. STR compounds induce the activation and expansion of specific T cells outside of the tumor microenvironment and redirect the T cells to attack the tumor cells.
Naptumomab estafenatox was licensed from Active Biotech in 2016.
About Active Biotech:
Active Biotech A.B (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer.
About Durvalumab:
Durvalumab, a human monoclonal antibody directed against PD-L1, blocks PD-L1 interaction with PD-1 and CD80 on T cells, countering the tumor’s immune-evading tactics and inducing an immune response. As part of a broad development program, durvalumab is being investigated as monotherapy and in combination with immuno-oncology, small molecules, and chemotherapies across a range of tumors and stages of disease.

Various statements in this release concerning future expectations constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may,” "expects,” "anticipates,” "believes,” and "intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors” sections of recent annual reports filed by the parties to this release. In addition, any forward-looking statements represent the parties’ views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. The parties do not assume any obligation to update any forward-looking statements unless required by law.

April 16, 2018 - Chicago, IL
NeoTX was awarded a poster session at the prestigious AACR conference in Chicago.

The information presented can be found at the following link:!/4562/presentation/9330

Our Partner has put out the information in a related link

December 2017 - Rehovot Israel
NeoTX is featured in Haaretz Magazine

NeoTX, an Immuno-Oncology drug development company, was featured in the December edition of their business magazine, highlighting Anyara

Anyara is a TTS (Tumor Targeting Superantigen) compund that enhances the ability of the immune system to recognize a tumor.
See the online version on page 41 here. For the pdf download, please click here.

December 2017 - Rehovot Israel
NeoTX closes $8.8MM Series B funding

NeoTX, an Immuno-Oncology drug development company, has raised over $8,750,000 in Series B funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg.

Total funds raised to date is nearly $18MM.

Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I continue to be extremely proud of the high quality team we have been able to attract, and the faith that our investors have placed in our ability to succeed. We continue to make progress and are excited by the developments in the immuno-oncology market."

October 2016 - Rehovot Israel
NeoTX closes $9.2MM Series A funding

NeoTX, an Immuno-Oncology drug development company, has raised over $9,200,000 in Series A funding from investors including Starr Ventures, a fund led by former AIG CEO Hank Greenberg.

Biotech entrepreneur CEO, Dr. Asher Nathan, stated "I am extremely proud of the high quality senior management team we have been able to attract, and the faith that our Series A investors have placed in our ability to succeed. We are extremely excited by the steps we have been able to accomplish early in our existence."

October 2016
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology

Lund (Sweden) and Tel Aviv (Israel), October 26th 2016 – Active Biotech AB (NASDAQ OMX NORDIC: ACTI) and NeoTX Therapeutics Ltd. announced today that they have entered into a licensing agreement for Active Biotech’s investigational compound Naptomumab estafenatox (“ANYARA”) for cancer immunotherapy. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug. This partnership is a key milestone in NeoTX's strategy to bring tumor recognition enhancing therapeutics to the market.

"We are very enthusiastic about our collaboration with Active Biotech. At NeoTX, we are strongly committed to developing innovative immunotherapies for unmet medical needs. "Active Biotech brings to our collaboration outstanding scientific and intellectual capital, and a powerful commitment to positively impact the treatment of cancer," said Asher Nathan, Chief Executive Officer of NeoTX.

Dr. Marcel Rozencweig, Chief Medical Officer of NeoTX and former Head of Global Clinical Oncology Research at BMS said “We are looking forward to developing ANYARA for immuno-oncology applications. We believe that the ANYARA technology is well suited to increase tumor recognition by the immune system and has demonstrated synergistic activity in combination with checkpoint inhibitors in animal models. As such, ANYARA would be attractive in combination with checkpoint inhibitors whose efficacy can be limited by poor tumor recognition”.

“We are excited about the partnership with NeoTX, who we consider as an ideal partner for ANYARA. This partnership constitutes the next step in the clinical development, as well as the commercialization strategy, for the project.” said Tomas Leanderson, President & CEO of Active Biotech.

About the agreement
Under the terms of the agreement, Active Biotech grants NeoTX exclusive rights to develop and commercialize ANYARA worldwide in cancer indications. The total deal value amounts to $71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech will receive $250 000 as an initial payment upon signing. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales.

ANYARA is a TTS (Tumor Targeting Superantigen) compound that increases the ability of the immune system to recognize the tumor. Synergy has been reported in vivo with a combination of ANYARA and a checkpoint inhibitor in an experimental tumor model. Clinically, the development of ANYARA has primarily been focused on cancer indications with a high unmet medical need. Positive data was reported from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent (monotherapy) and in combination with an established tumor therapy - docetaxel (Taxotere®) - in patients with advanced cancer. The results showed that ANYARA was well tolerated both as monotherapy and in combination with docetaxel, and increased tumor recognition by T cells.

A Phase 2/3 trial of ANYARA in combination with interferon alpha in renal cell cancer demonstrated acceptable safety but did not meet its primary efficacy endpoint in the ITT population. The upcoming clinical trial will be done in combination with drugs that inhibit checkpoint dampening of the immune system, a combination strategy in line with the mode of action of ANYARA and supported by preclinical data.

NeoTX Therapeutics Ltd. is based in Rehovot Israel and is a clinical stage immuno-oncology company. NeoTX was founded to bring safe and effective immunotherapies to cancer patients. Please visit for more information.

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington’s disease. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit for more information.

For further information, please contact:

NeoTX Therapeutics Ltd.
Asher Nathan CEO
Tel: +1 609 718 2305 x 1

Robert Harow, CFO
Tel: +1 609 718 2305 x 2

(Corp.Reg. No. 515220929)
2 Pekeris Street
Rehovot, Israel
Tel: +1 609 718 2305
Tel: +972 3 912 5853

Active Biotech AB
Tomas Leanderson, President and CEO
Tel: +46 46 19 20 95

Hans Kolam, CFO
Tel: +46 46 19 20 44

(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund, Sweden
Tel: +46 46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 am CET on October 26, 2016.

Contact Us

2 Pekeris Street
Rehovot, Israel 7670202
Phone: +1 609 718 2305
Phone: +972 3 912 5853
Fax: +972 8 936 8584

Contact NeoTX

Copyright NeoTX © 2019 | All Rights Reserved